BIONTECH SE (BNTX) News
BIONTECH SE (BNTX)
Today's Latest Price: $101.87 USD
Updated Nov 24 4:00pm
Add BNTX to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
Filter BNTX News Items
BNTX News Results
| Event/Time | Symbol | Company | News Detail | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest BNTX News From Around the Web
Below are the latest news stories about BioNTech SE that investors may wish to consider to help them evaluate BNTX as an investment opportunity.
Moderna, Pfizer & BioNTech, and AstraZeneca and the University of Oxford's COVID-19 Vaccine Trials are Entering the Final Stage of DevelopmentDUBLIN, Oct. 2, 2020 /PRNewswire/ -- ResearchAndMarkets.com published a new article on the vaccine industry "COVID-19 Vaccine Trials are Entering the Final Stage of Development" Johnson & Johnson has begun final stage testing of its COVID-19 vaccine candidate. The company will trial the… |
COVID-19 Vaccine & Therapeutics Clinical Trial Analysis 2020 Featuring Major Players - Pfizer, GSK, Inovio Pharma, J&J, Novavax, Heat Biologics, Sanofi, BioNTech, Vaxart, and Vir Biotechnology - ResearchAndMarkets.comDUBLIN--(BUSINESS WIRE)--The "COVID-19 Vaccine & Therapeutics Clinical Trial Analysis 2020" report has been added to ResearchAndMarkets.com's offering. COVID-19 Vaccine & Therapeutics Clinical Trial Analysis 2020 provides the strategists, marketers and senior management with the critical information they need to assess the global COVID-19 vaccine & therapeutics clinical trial analysis 2020 market. Major players in the COVID-19 vaccine and therapeutics clinical trial analysis market |
Dr. Fauci just said something surprising about coronavirus vaccines and face masksSeveral coronavirus vaccine trials will soon be finished and some of the frontrunners might be deemed safe and effective for emergency use. Health officials from the World Health Organization and Dr. Anthony Fauci warn that the arrival of COVID-19 vaccines won't be enough to reduce the transmission of the illness anytime soon. Fauci says that precautionary measures including face masks, social distancing, and frequent handwashing will need to continue even after vaccines arrive. The FDA will host a significant coronavirus vaccine meeting in just a few weeks, at which point we might find out more details about the progress of experimental drugs that have reached the final phase of testing. Vaccine candidates from AstraZeneca/Oxford, Pfizer/BioNTech, and Moderna have Phase 3 trials underw... |
COVID-19 vaccine credibility collapsing - MacroBusinessIt’s not the fruitloop anti-vaxxers fault, either. It’s governments. Via Bloomberg: The Covid-19 vaccine trial designed by Pfizer Inc. and its German partner BioNTech SE may allow them to find whether their shot works before their fastest-moving rivals. The companies plan a first look after a mere 32 coronavirus infections have accumulated in their massive |
Experts Worry As Leading COVID-19 Vaccines Adopt Trial Shortcuts In "Rush For Results"Experts Worry As Leading COVID-19 Vaccines Adopt Trial Shortcuts In "Rush For Results" Tyler Durden Tue, 09/22/2020 - 13:05 As doubts about the FDA's credibility grow as the agency awaits the initial results from the frontrunner's "Phase 3" trials, the leading vaccine makers are working to further expedite the approval process by streamlining procedures to try and make a determination about whether their vaccine "works or not" within the next month or so. The issue, as Bloomberg reports , is that the leading vaccine companies are shooting for low targets for the number of confirmed infections among the tens of thousands of patients they've recruited for their trials. Remember, half of the test subjects have been given a vaccine, while the other half haven't. Leading candidates will repo... |
COVID-19 Vaccine Car CrashNews in the past week has not been encouraging that COVID-19 vaccine development is on track. In fact, claims by President Trump about the likely end of the pandemic seem quaintly like groundhog day as he made a similar claim back in early April when the number of US COVID-19... |
Inovio Defies Market-Wide Weakness: What's Behind The Rally?Inovio Pharmaceuticals Inc (NASDAQ: INO ) shares have been seeing strong momentum ever since hitting a near-term low of $8.78 on Sept. 4. Inovio Weathers Market Downturn: Inovio's stock rose as high as $18.55 Wednesday before pulling back slightly in the next session. Reversing course, Inovio rebounded Friday to settle the session at $17, a gain of about 94% from the Sept. 4 low. The momentum is continuing in Monday's session, with the stock holding up despite the major averages plunging by about 2% and across-the-board weakness seen among shares of coronavirus vaccine developers. The strength comes despite the odds that are by the Plymouth, Pennsylvania-based company. Inovio's DNA Vaccine Play: Moderna Inc (NASDAQ: MRNA ), Pfizer Inc. (NYSE: PFE )/ BioNTech SE – ADR (NASDAQ: BNTX ) and... |
Pfizer vaccine early trials bet on win against COVID-19In recent weeks, Pfizer has said it should know by the end of October whether the vaccine, developed together with Germany's BioNTech SE, is safe and effective |
BioNTech to acquire manufacturing site in Germany to scale up COVID-19 vaccine productionBioNTech (BNTX) signs a share purchase agreement with Novartis (NVS) to acquire their GMP certified manufacturing facility in Marburg, Germany.The manufacturing site will expand BioNTech’s COVID-19 vaccine production capacity by up to 750M doses per year, or over 60M doses per month, once fully operational.The Company expects to produce up... |
BioNTech buys German site to ramp up Covid-19 vaccine productionNo summary available. |
